Daily Stock Analysis, ADMS, Adamas Pharmaceuticals Inc, priceseries

Adamas Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
11.27
Close
10.99
High
11.78
Low
10.84
Previous Close
11.24
Daily Price Gain
-0.25
YTD High
11.78
YTD High Date
Feb 21, 2019
YTD Low
8.22
YTD Low Date
Jan 2, 2019
YTD Price Change
1.92
YTD Gain
21.17%
52 Week High
32.90
52 Week High Date
May 18, 2018
52 Week Low
7.42
52 Week Low Date
Dec 20, 2018
52 Week Price Change
-16.42
52 Week Gain
-59.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 1. 2017
16.27
Jun 20. 2017
17.23
13 Trading Days
5.91%
Link
LONG
Oct 27. 2017
19.51
Nov 14. 2017
26.69
12 Trading Days
36.81%
Link
LONG
Nov 16. 2017
27.69
Dec 13. 2017
33.93
18 Trading Days
22.54%
Link
LONG
Apr 17. 2018
25.01
May 4. 2018
28.42
13 Trading Days
13.62%
Link
Company Information
Stock Symbol
ADMS
Exchange
NasdaqGM
Company URL
http://www.adamaspharma.com
Company Phone
510-450-3554
CEO
Gregory T. Went
Headquarters
California
Business Address
1900 POWELL ST., SUITE 750, EMERYVILLE, CA 94608
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001328143
About

Adamas Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in discovering chrono-synchronous therapies. It involves in the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Description

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's products under development include ADS-4101, a chrono-synchronous lacosamide therapy that has completed first Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.